1. Home
  2. INAB

as of 11-20-2026 3:59pm EST

$0.75
$0.02
-2.93%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Founded: 2016 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 11.8M IPO Year: 2020
Target Price: $7.00 AVG Volume (30 days): 69.2K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.74 EPS Growth: -678.95
52 Week Low/High: $0.72 - $2.73 Next Earning Date: 11-05-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -1.05 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered INAB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Precision: 18.18%
18.18%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-2.23%

$0.81

Act: +16.87%

5D

-9.76%

$0.75

Act: -1.81%

20D

+110.00%

$1.74

Price: $0.83 Prob +5D: 0% AUC: 1.000
0001193125-26-449820

EX-99.1

2 inab-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

• Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

• Received third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune disease

• Remain on track to report initial in vivo (animal) data for INB-619 by year-end 2026

NEW YORK, Nov. 5, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the third quarter ended September 30, 2026.

“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform,” said William Ho, CEO and co-founder of IN8bio. “It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”

Third Quarter 2026 Business Highlights

Strengthened Research and Development Leadership

• Oxana Polyakova, Ph.D., joined IN8bio as Senior Vice President of Research & Development in September 2026, bringing 20 years of experience in γδ T cell biology, immunology, oncology, TCE and biologics development.

• Dr. Polyakova joins IN8bio from LAVA Therapeutics, a clinical-stage immuno-oncology company developing bispecific γδ T cell engagers, where she served as Chief Scientific Officer (CSO). She previously also served as CSO at LIfT Biosciences. She was Scientific Founder and Head of Discovery at Adaptate Biotherapeutics, a γδ TCE focused spinout of GammaDelta Therapeutics, which was acquired by Takeda. At Adaptate, she designed and led its R&D strategy, established its laboratories and built its R&D team which has a

program currently in the clinic. Dr. Polyakova served as the Protein and Molecular Leader at GammaDelta Therapeutics Limited that was also acquired by Takeda.

• She will help lead R&D efforts to accelerate IN8bio's γδ TCE pipeline toward clinical development.

Publication of INB-200 Phase 1 Data in GBM

• In July 2026, IN8bio announced the publication of peer-reviewed clinical data from the Phase 1 trial of INB-200 (DeltEx™ DRI) in patients with newly diagnosed GBM in the Journal of Clinical Oncology(JCO), titled “Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma.”

Advancing γδ T Cell Engager Platform (INB-619)

• Continued advancing proprietary INB-600 platform of novel pan-γδ TCEs designed to selectively engage and expand γδ T cells to eliminate disease-associated target cells while potentially improving tolerability compared with conventional CD3-targeting TCEs.

• Advancing INB-619 through preclinical studies for potential applications in oncology and autoimmune diseases.

• INB-619 was included in a review of next-generation immune cell engagers for B cell depletion in autoimmune disease published in Nature Reviews Drug Discovery in October 2026, which noted its ability to activate and expand both tissue-resident Vδ1 and circulating Vδ2 γδ T cells in vitro.

• Remain on track to report initial in vivo preclinical data for INB-619 by year-end 2026.

Third Quarter 2026 Financial Highlights

• Research and Development (R&D) expenses: R&D expenses were $2.6 million for the three months ended September 30, 2026, compared with $2.1 million for the comparable prior year period. This amount includes non-cash items such as stock-based compensation (SBC) and depreciation of $0.4 million for the three months ended September 30, 2026. The increase was due primarily to preclinical costs associated with the Company’s T cell engager platform.

• General and administrative (G&A) expenses: G&A expenses were $2.1 million for the three months ended September 30, 2026, compared with $1.9 million for the comparable prior year period. This amount includes non-cash items such as SBC and depreciation of $0.3 million for the three months ended September 30, 2026. The increase was due primarily to higher spending on professional services.

• Net loss: The Company reported a net loss of $4.6 million, or $0.24 per basic and diluted common share, for the three months ended September 30, 2026, compared with a net loss of $3.9 million, or $0.85 per basic and diluted common share, for the compara

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 6, 2026 · 100% conf.

AI Prediction SELL

1D

-1.67%

$0.97

Act: -1.03%

5D

-9.32%

$0.90

20D

+110.48%

$2.08

Price: $0.99 Prob +5D: 0% AUC: 1.000
0001193125-26-337944

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786364511.c9f4689d

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-1.82%

$1.57

Act: +0.00%

5D

-10.12%

$1.44

Act: -0.63%

20D

+121.38%

$3.54

Act: -9.38%

Price: $1.60 Prob +5D: 0% AUC: 1.000
0001193125-26-212128

EX-99.1

4 inab-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

• Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026

• Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026

• Hosting R&D Day on May 21, 2026 in New York City

NEW YORK, May 7, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2026.

“In the first quarter of 2026, we continued to advance our next-generation TCE platform and clinical programs,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “Our encouraging GBM data positions us to engage the FDA on potential regulatory pathways forward, and we expect to deliver meaningful preclinical, regulatory and clinical milestones across our pipeline this year. As industry interest in novel TCEs accelerates, our next-generation platform is designed to address the key challenges in TCE development. We believe IN8bio is well positioned to create meaningful value for patients and shareholders in 2026 and beyond. We look forward to sharing further updates across our programs at our upcoming R&D Day in New York City on May 21, 2026.”

Key Highlights

Advancing Next-Generation Gamma-Delta T Cell Engager Platform (INB-619)

• Continued to advance our internally developed INB-600 platform of novel γδ T cell engagers, designed to potently eliminate targets such as CD19, potentially reduce toxicities such as cytokine release syndrome (CRS) and widen the therapeutic window over traditional CD3-targeting engagers.

• Presented encouraging preclinical data for INB-619, a CD19-targeting γδ T cell engager for oncology and autoimmune diseases. The data showed complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release (IL-6, TNF-α), reinforcing the platform’s differentiation and therapeutic potential.

• Progressing INB-619 into IND-enabling studies, with initial animal data expected in 2026.

Presented Clinical Data Demonstrating Durable Survival Improvements in Newly Diagnosed Glioblastoma

In January 2026, IN8bio reported updated data as of December 31, 2025, from its Phase 1 (INB-200) and Phase 2 (INB-400) clinical trials evaluating DeltEx drug resistant immunotherapy (DRI) γδ T cells in patients with newly diagnosed GBM. The data included a concurrent standard-of-care (SOC) control group enrolled at the same time and clinical sites as treated patients.

• Median progression-free survival (mPFS) for repeat dose patients was 13.0 months versus 6.6 months for SOC patients (+97% improvement).

• Median overall survival (mOS) in repeat dose patients is still climbing, currently at 17.2+ months as of December 31, 2025, surpassing the 13.2-months for the SOC control arm.

• Several patients remained progression-free beyond two years, including one grade 4, IDH-mutant glioma patient who remains progression-free with no additional therapy for more than 4.5 years.

• No dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), neurotoxicity (ICANS), tumor inflammation-associated neurotoxicity (TIAN) or other unexpected severe adverse events were reported.

• Updated mOS results to be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (Abstract 2077, Poster 442) on June 1, from 1:30 - 4:30 p.m. CDT.

IN8bio Research & Development Day 2026

• IN8bio will host its R&D Day on May 21, 2026 (9:00 - 11:30 a.m. EDT), in New York City.

• The event will feature presentations on the Company’s γδ TCE platform targeting oncology and autoimmune diseases.

• The Company will also provide updates on its clinical program in GBM, including a clinical perspective from renowned neuro-oncologist Dr. David Reardon, Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.

• Register Online: https://investors.in8bio.com/news-events/events-presentations.

Upcoming Conferences & Anticipated Milestones

International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting (Dublin, Ireland)

• Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma

Poster Details: 1253 Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 - 2:30 p.m. EDT)

• Title: Lean Infrastructure for CGT Early-Stage Companies: Leveraging Integrated Digital Platforms to Achieve Sustainable Operation Efficiency and Scalable Compliance

Poster Details: 801 Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 - 2:30 p.m. EDT)

American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Me

Share on Social Networks: